Iterum TherapeuticsITRMF
13F holders, Q3 2024 (September 30)15holders +1
6new positions
5sold out
$1.09avg. 13F price*
At the end of Q3 2024, 15 institutions reported holding Iterum Therapeutics PLC (ITRMF) in their 13F filings, up 1 from Q2 2024. 6 opened new positions and 5 sold out. The largest holders were Armistice Capital, LLC ($1.5M), New Leaf Venture Partners, L.L.C. ($376K) and Apollon Financial, LLC ($245K).
- Company
- Iterum Therapeutics PLC
- CUSIP
- G6333L200
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 6 | $1.6M |
| Exits | 5 | $118K |
All 13F filers, Q2 2024 → Q3 2024: 1,713,125 shares bought and 103,937 shares sold, net +1,609,188 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 15 holders
| Armistice Capital, LLC | 0.04% | New | 1,340,000 | $1.5M |
| New Leaf Venture Partners, L.L.C. | 0.39% | Add +255.4% | 345,020 | $376K |
| Apollon Financial, LLC | 0.07% | No change | 224,750 | $245K |
| Alpine Global Management, LLC | 0.02% | New | 64,833 | $71K |
| XTX Topco Ltd | 0.00% | New | 33,040 | $36K |
| Two Sigma Securities, LLC | 0.00% | New | 14,947 | $16K |
| Geode Capital Management, LLC | 0.00% | New | 12,370 | $13K |
| Morgan Stanley | 0.00% | No change | 5,479 | $6K |
| Activest Wealth Management | 0.00% | No change | 133 | $145 |
| Wells Fargo & Company | 0.00% | Reduce -93.4% | 85 | $93 |
| Planning Capital Management Corp | 0.00% | No change | 40 | $44 |
| HM Payson & Co. | 0.00% | No change | 3 | $4 |
| National Bank of Canada | 0.00% | No change | 2 | $2 |
| JPMorgan Chase & Co. | 0.00% | New | 1 | $1 |
| UBS Group AG | 0.00% | No change | 1 | $1 |
"% of holder's portfolio" is ITRMF's weight in each manager's 13F, not the share of Iterum Therapeutics PLC the manager owns.